<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122680</url>
  </required_header>
  <id_info>
    <org_study_id>205.424</org_study_id>
    <secondary_id>2009-017745-55</secondary_id>
    <nct_id>NCT01122680</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma</brief_title>
  <official_title>A Phase II Randomised, Double-blind, Placebo-controlled, Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Adolescents (12 to 17 Yrs Old) With Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate the efficacy and safety of tiotropium 1.25
      mcg (2 actuations of 0.625 mcg), tiotropium 2.5 mcg (2 actuations of 1.25 mcg) and tiotropium
      5 mcg (2 actuations of 2.5 mcg) once daily in the evening delivered by the Respimat inhaler
      in adolescents (12 to 17 yrs) with moderate persistent asthma, compared to placebo and on top
      of maintenance therapy with an inhaled corticosteroid controller medication. It is a
      randomised, double-blind, placebo-controlled Phase II trial with incomplete cross-over
      design. Patients need to be still symptomatic, i. e. not fully controlled with their
      maintenance treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Individual Measurements Response at Each Time-point</measure>
    <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
    <description>Individual FEV1 measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Peak (0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Trough Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Individual Measurements at Each Time-point</measure>
    <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
    <description>Individual FVC measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow (FEF) 25-75% Individual Measurements Response at Each Time Point</measure>
    <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
    <description>FEF 25-75% is the mean forced expiratory flow between 25% and 75% of the FVC determined at the end of the 4-week treatment period. This is often referred to as the maximum midexpiratory flow. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Morning Peak Expiratory Flow (PEF) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Evening PEF Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Puffs of Rescue Medication Per Day</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>4 weeks</time_frame>
    <description>ACQ is a questionnaire consisting of a seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nighttime Awakenings</measure>
    <time_frame>Baseline and last week of treatment (week 4)</time_frame>
    <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
    <description>inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
    <description>inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo inhalation solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients and legally accepted caregiver(s) must sign and date an Informed Consent
             form consistent with Good Clinical Practice (GCP) guidelines of the International
             Conference on Harmonisation of Technical Requirements for Registration of
             Pharmaceuticals for Human Use (ICH) and local legislation prior to participation in
             the trial.

          2. Male or female patients between 12 and 17 years of age.

          3. All patients must have at least a 3 months history of asthma and fulfill the
             diagnostic criteria of moderate persistent asthma, according to the current Global
             Initiative for Asthma (GINA) guidelines at the time of enrolment into the trial.

          4. All patients must have been on maintenance treatment with inhaled corticosteroids at a
             stable medium dose for at least 4 weeks before Visit 1.

          5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and prior
             to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean
             score of equal or above 1.5.

          6. All patients must have a pre-bronchodilator FEV1 above 60% and less than or equal 90%
             of predicted normal at Visit 1. Variation of absolute FEV1 values of Visit 1
             (pre-bronchodilator) as compared to Visit 2 (pre-dose) must be within ± 30%.

          7. All patients must have an increase in FEV1 of equal or above 12% and 200 mL 15 min.
             after 400 mcg salbutamol (albuterol) at Visit 1. If patients in the lower age range
             (e.g., 12 to 14 year olds) exhibit a very small total lung volume, positive
             reversibility testing might be based solely on the relative (12%) post-bronchodilator
             response.

          8. All patients should be never-smokers or ex-smokers who stopped smoking at least one
             year prior to enrolment.

          9. Patients should be able to use the Respimat® inhaler correctly.

         10. Patients must be able to perform all trial related procedures including technically
             acceptable spirometric manoeuvres, according to American Thoracic Society (ATS)
             standards and the use of the electronic diary/peak flow meter.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. Patients with a history of congenital or acquired heart disease, and/or have been
             hospitalised for cardiac syncope or failure during the past year.

          3. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention (e. g. pacemaker implantation) or a change in drug
             therapy within the past year.

          4. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          5. Patients with lung diseases other than asthma, e.g. cystic fibrosis (CF). In case of
             ex-premature infants, a history of significant bronchopulmonary dysplasia (BPD) will
             be regarded as exclusion criterion

          6. Patients with significant alcohol or drug abuse within the past two years.

          7. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride
             (BAC), ethylenediaminetetraacetic acid (EDTA) or any other components of the
             tiotropium inhalation solution.

          8. Pregnant or nursing adolescent female patients, including female patients with a
             positive Beta HCG (serum pregnancy) testing at screening (visit 1).

          9. Sexually active female patients of child-bearing potential not using a highly
             effective method of birth control.

         10. Patients with a known narrow-angle glaucoma, or any other disease where
             anticholinergic treatment is contraindicated.

         11. Patients with renal impairment, as defined by a creatinine clearance less than 50
             mL/min/1.73 m2 body surface area (BSA) as calculated by Schwartz Formula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.424.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boys Town</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.38604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.38605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.424.38602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Slovenia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <results_first_submitted>April 10, 2012</results_first_submitted>
  <results_first_submitted_qc>May 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2012</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this incomplete crossover design, 105 patients were randomised to one of four sequences (in general terms, ABC, BDA, CAD or DCB). Whilst there were 4 possible treatments, A, B, C and D, each patient would receive a maximum of 3 different treatments. Hence, approximately 75 patients would receive each of A, B, C and D at any timepoint.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tio R5/Placebo/Tio R1.25</title>
          <description>Patients treated with Tiotropium 5 mcg in Phase I, with a matching Placebo in Phase II and with Tiotropium 1.25 mcg in Phase III. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off-treatment periods) between treatments.</description>
        </group>
        <group group_id="P2">
          <title>Tio R1.25/Tio R5/Tio R2.5</title>
          <description>Patients treated with Tiotropium 1.25 mcg in Phase I, with Tiotropium 5 mcg in Phase II and with Tiotropium 2.5 mcg in Phase III. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off-treatment periods) between treatments.</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Tio R2.5/Tio R5</title>
          <description>Patients treated with a matching Placebo in Phase I, with Tiotropium 2.5 mcg in Phase II and with Tiotropium 5 mcg in Phase III. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off-treatment periods) between treatments.</description>
        </group>
        <group group_id="P4">
          <title>Tio R2.5/Tio R1.25/Placebo</title>
          <description>Patients treated with Tiotropium 2.5 mcg in Phase I, with Tiotropium 1.25 mcg in Phase II and with a matching Placebo in Phase III. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off-treatment periods) between treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29">Entered this study period.</participants>
                <participants group_id="P2" count="26">Entered this study period.</participants>
                <participants group_id="P3" count="26">Entered this study period.</participants>
                <participants group_id="P4" count="24">Entered this study period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">Completed treatment in this crossover period.</participants>
                <participants group_id="P2" count="25">Completed treatment in this crossover period.</participants>
                <participants group_id="P3" count="26">Completed treatment in this crossover period.</participants>
                <participants group_id="P4" count="24">Completed treatment in this crossover period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Entered this study period.</participants>
                <participants group_id="P2" count="25">Entered this study period.</participants>
                <participants group_id="P3" count="26">Entered this study period.</participants>
                <participants group_id="P4" count="24">Entered this study period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">Completed treatment in this crossover period.</participants>
                <participants group_id="P2" count="25">Completed treatment in this crossover period.</participants>
                <participants group_id="P3" count="26">Completed treatment in this crossover period.</participants>
                <participants group_id="P4" count="23">Completed treatment in this crossover period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">Entered this study period.</participants>
                <participants group_id="P2" count="25">Entered this study period.</participants>
                <participants group_id="P3" count="26">Entered this study period.</participants>
                <participants group_id="P4" count="23">Entered this study period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">Completed treatment in this crossover period.</participants>
                <participants group_id="P2" count="24">Completed treatment in this crossover period.</participants>
                <participants group_id="P3" count="26">Completed treatment in this crossover period.</participants>
                <participants group_id="P4" count="23">Completed treatment in this crossover period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total.</title>
          <description>Total number of patients randomised and treated at all in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in 1s (FEV1)</title>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.742" spread="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</title>
        <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>The Full analysis set (FAS) is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period. This patient set is therefore FAS reduced to patients with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</title>
          <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>The Full analysis set (FAS) is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period. This patient set is therefore FAS reduced to patients with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.489" spread="0.047"/>
                    <measurement group_id="O2" value="0.556" spread="0.047"/>
                    <measurement group_id="O3" value="0.546" spread="0.047"/>
                    <measurement group_id="O4" value="0.602" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <p_value_desc>First step of closed testing procedure, where the active treatments are compared to placebo. If this statisical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.</p_value_desc>
            <method>Mixed model repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tio R2.5 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1484</p_value>
            <p_value_desc>Second step of closed testing procedure. If this statisical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.</p_value_desc>
            <method>Mixed effect repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tio R1.25 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0664</p_value>
            <p_value_desc>This test is considered as descriptive.</p_value_desc>
            <method>Mixed effect repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Tio R1.25</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Tio R2.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tio R2.5 minus Tio R1.25</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.088</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.292" spread="0.045"/>
                    <measurement group_id="O2" value="0.384" spread="0.045"/>
                    <measurement group_id="O3" value="0.353" spread="0.045"/>
                    <measurement group_id="O4" value="0.442" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
        <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
          <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.363" spread="0.045"/>
                    <measurement group_id="O2" value="0.455" spread="0.045"/>
                    <measurement group_id="O3" value="0.434" spread="0.045"/>
                    <measurement group_id="O4" value="0.497" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Individual Measurements Response at Each Time-point</title>
        <description>Individual FEV1 measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
        <population>FAS with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Individual Measurements Response at Each Time-point</title>
          <description>Individual FEV1 measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.292" spread="0.045"/>
                    <measurement group_id="O2" value="0.384" spread="0.045"/>
                    <measurement group_id="O3" value="0.353" spread="0.045"/>
                    <measurement group_id="O4" value="0.442" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.337" spread="0.047"/>
                    <measurement group_id="O2" value="0.456" spread="0.047"/>
                    <measurement group_id="O3" value="0.407" spread="0.047"/>
                    <measurement group_id="O4" value="0.486" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.353" spread="0.048"/>
                    <measurement group_id="O2" value="0.456" spread="0.048"/>
                    <measurement group_id="O3" value="0.416" spread="0.048"/>
                    <measurement group_id="O4" value="0.505" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.394" spread="0.047"/>
                    <measurement group_id="O2" value="0.467" spread="0.048"/>
                    <measurement group_id="O3" value="0.453" spread="0.047"/>
                    <measurement group_id="O4" value="0.501" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.396" spread="0.048"/>
                    <measurement group_id="O2" value="0.467" spread="0.048"/>
                    <measurement group_id="O3" value="0.489" spread="0.048"/>
                    <measurement group_id="O4" value="0.497" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Peak (0-3h) Response</title>
        <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Peak (0-3h) Response</title>
          <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.546" spread="0.049"/>
                    <measurement group_id="O2" value="0.554" spread="0.049"/>
                    <measurement group_id="O3" value="0.554" spread="0.048"/>
                    <measurement group_id="O4" value="0.548" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Trough Response</title>
        <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Trough Response</title>
          <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" spread="0.047"/>
                    <measurement group_id="O2" value="0.375" spread="0.047"/>
                    <measurement group_id="O3" value="0.381" spread="0.047"/>
                    <measurement group_id="O4" value="0.400" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
        <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
          <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.413" spread="0.046"/>
                    <measurement group_id="O2" value="0.441" spread="0.046"/>
                    <measurement group_id="O3" value="0.417" spread="0.045"/>
                    <measurement group_id="O4" value="0.429" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Individual Measurements at Each Time-point</title>
        <description>Individual FVC measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
        <population>FAS with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Individual Measurements at Each Time-point</title>
          <description>Individual FVC measurements at each time-point (&quot;personal best&quot;). Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" spread="0.047"/>
                    <measurement group_id="O2" value="0.375" spread="0.047"/>
                    <measurement group_id="O3" value="0.381" spread="0.047"/>
                    <measurement group_id="O4" value="0.400" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.397" spread="0.049"/>
                    <measurement group_id="O2" value="0.434" spread="0.049"/>
                    <measurement group_id="O3" value="0.394" spread="0.049"/>
                    <measurement group_id="O4" value="0.409" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.417" spread="0.049"/>
                    <measurement group_id="O2" value="0.443" spread="0.050"/>
                    <measurement group_id="O3" value="0.387" spread="0.049"/>
                    <measurement group_id="O4" value="0.448" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429" spread="0.048"/>
                    <measurement group_id="O2" value="0.438" spread="0.048"/>
                    <measurement group_id="O3" value="0.444" spread="0.048"/>
                    <measurement group_id="O4" value="0.423" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.430" spread="0.048"/>
                    <measurement group_id="O2" value="0.461" spread="0.048"/>
                    <measurement group_id="O3" value="0.454" spread="0.048"/>
                    <measurement group_id="O4" value="0.456" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow (FEF) 25-75% Individual Measurements Response at Each Time Point</title>
        <description>FEF 25-75% is the mean forced expiratory flow between 25% and 75% of the FVC determined at the end of the 4-week treatment period. This is often referred to as the maximum midexpiratory flow. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks (10 min pre-dose, 30 min, 1,2,3 hours post-dose)</time_frame>
        <population>FAS with non-missing FEF data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow (FEF) 25-75% Individual Measurements Response at Each Time Point</title>
          <description>FEF 25-75% is the mean forced expiratory flow between 25% and 75% of the FVC determined at the end of the 4-week treatment period. This is often referred to as the maximum midexpiratory flow. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing FEF data</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="0.081"/>
                    <measurement group_id="O2" value="0.533" spread="0.082"/>
                    <measurement group_id="O3" value="0.380" spread="0.082"/>
                    <measurement group_id="O4" value="0.566" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.268" spread="0.083"/>
                    <measurement group_id="O2" value="0.643" spread="0.084"/>
                    <measurement group_id="O3" value="0.513" spread="0.084"/>
                    <measurement group_id="O4" value="0.647" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.321" spread="0.087"/>
                    <measurement group_id="O2" value="0.655" spread="0.087"/>
                    <measurement group_id="O3" value="0.569" spread="0.087"/>
                    <measurement group_id="O4" value="0.641" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" spread="0.088"/>
                    <measurement group_id="O2" value="0.678" spread="0.089"/>
                    <measurement group_id="O3" value="0.607" spread="0.089"/>
                    <measurement group_id="O4" value="0.622" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 hr response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.329" spread="0.083"/>
                    <measurement group_id="O2" value="0.662" spread="0.084"/>
                    <measurement group_id="O3" value="0.616" spread="0.084"/>
                    <measurement group_id="O4" value="0.620" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Morning Peak Expiratory Flow (PEF) Response</title>
        <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing morning PEF data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Morning Peak Expiratory Flow (PEF) Response</title>
          <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing morning PEF data</population>
          <units>Litre/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.267" spread="6.152"/>
                    <measurement group_id="O2" value="18.613" spread="6.118"/>
                    <measurement group_id="O3" value="23.185" spread="6.146"/>
                    <measurement group_id="O4" value="20.491" spread="6.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Evening PEF Response</title>
        <description>Mean evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing evening PEF data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Evening PEF Response</title>
          <description>Mean evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing evening PEF data</population>
          <units>Litre/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.552" spread="6.098"/>
                    <measurement group_id="O2" value="5.985" spread="6.089"/>
                    <measurement group_id="O3" value="18.971" spread="6.043"/>
                    <measurement group_id="O4" value="16.565" spread="5.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Puffs of Rescue Medication Per Day</title>
        <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with non-missing data for rescue medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Puffs of Rescue Medication Per Day</title>
          <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing data for rescue medication</population>
          <units>Puffs/day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.412" spread="0.155"/>
                    <measurement group_id="O2" value="-0.635" spread="0.156"/>
                    <measurement group_id="O3" value="-0.521" spread="0.154"/>
                    <measurement group_id="O4" value="-0.528" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</title>
        <description>ACQ is a questionnaire consisting of a seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS with non-missing ACQ data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</title>
          <description>ACQ is a questionnaire consisting of a seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing ACQ data</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.371" spread="0.078"/>
                    <measurement group_id="O2" value="1.189" spread="0.079"/>
                    <measurement group_id="O3" value="1.366" spread="0.078"/>
                    <measurement group_id="O4" value="1.287" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nighttime Awakenings</title>
        <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and last week of treatment (week 4)</time_frame>
        <population>FAS with non-missing data for nighttime awakenings</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nighttime Awakenings</title>
          <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with non-missing data for nighttime awakenings</population>
          <units>Night awakenings per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.086" spread="0.030"/>
                    <measurement group_id="O2" value="-0.027" spread="0.030"/>
                    <measurement group_id="O3" value="-0.074" spread="0.030"/>
                    <measurement group_id="O4" value="-0.066" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks + 30 days if in last period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E2">
          <title>Tio R1.25</title>
          <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E3">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E4">
          <title>Tio R5</title>
          <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

